News Conference News ESC 2025 BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension Todd Neale August 31, 2025
News Conference News AHA 2024 Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD Yael L. Maxwell November 16, 2024
News Conference News ESC 2024 Stop-or-Not: It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery Todd Neale August 30, 2024
News Conference News ACC 2024 TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP L.A. McKeown April 16, 2024
News Conference News ACC 2024 KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives Shelley Wood April 11, 2024
News Conference News AHA 2023 RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1 Caitlin E. Cox November 11, 2023
News Conference News ACC 2023 HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension Todd Neale March 08, 2023
News Conference News ESC 2022 CV Care Around Noncardiac Surgery: New ESC Guidelines Michael O'Riordan September 07, 2022
News Conference News ACC 2022 POISE-3: Two Perioperative BP Strategies Give Similar Results in Noncardiac Surgery Todd Neale April 06, 2022
News Conference News ESC 2021 STEP Trial Supports Lower BP Goal in Older Patients With Hypertension Todd Neale August 30, 2021
News Conference News AHA 2020 One Pill to Treat Them All: Polycap Strategy Sees Success in TIPS-3 Michael O'Riordan November 13, 2020
News Conference News Blood Pressure Insights in COVID-19: Watch for Drops and RAAS Red Flags L.A. McKeown September 10, 2020
News Conference News ESC 2020 Antihypertensives Cut CV Events Across BP Levels, Regardless of Prior CVD: BPLTTC Shelley Wood August 31, 2020
News Conference News AHA 2017 Long-Awaited Hypertension Guidelines Released at AHA Todd Neale November 13, 2017
News Conference News ESC 2016 Optimal Approach for BP Lowering Debated Amid New J-Curve Signals in Stable CAD Todd Neale September 09, 2016